Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.54 |
| ▸ | HTR3B | O95264 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 4/20 | 0.51 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59331 | 0.94 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL28885740 | 0.92 | ADRB1 (0.59) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14341118 | 0.89 | ADRB1 (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29471932 | 0.85 | KCNA5 (0.50) | KCNA5 | |
| SCHEMBL2426703 | 0.85 | KCNA5 (0.50) | KCNA5 | |
| SCHEMBL28161315 | 0.83 | EPHX2 (0.50) | KCNA5 | |
| SCHEMBL30424403 | 0.83 | ADRB1 (0.49) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31466211 | 0.80 | CACNA2D1 (0.48) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5543670 | 0.80 | L3MBTL3 (0.49) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3937241 | 0.79 | ADRB1 (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3945091-B1 | NOVEL VDAC1 INHIBITORS | ABARCEO AB (SE) | 2024-01-03 | — | — | EP | disclosed |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2023-11-02 | — | — | US | disclosed |
| WO-2022022846-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO AB (SE) | 2022-02-03 | — | — | WO | disclosed |
| EP-3945091-A1 | NOVEL VDAC1 INHIBITORS | Abarceo AB (SE) | 2022-02-02 | — | — | EP | disclosed |
| EP-3945091-A1 | NOVEL VDAC1 INHIBITORS | Abarceo AB (SE) | 2022-02-02 | — | — | EP | disclosed |
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| WO-2016091207-A1 | NITROMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG MANUFACTURING | 上海阳帆医药科技有限公司 | 2016-06-16 | — | — | WO | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | NISCH, CYP51A1, CYP4F11 | ADRB1 912/4885HTR3E 4626/4885HTR3B 3942/4885 |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | VDAC1, HVCN1, VDAC2 | ADRB1 1034/4885HTR3E 2238/4885HTR3B 1827/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | ADRB1 241/4885HTR3E 4205/4885HTR3B 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.